Outcome of patients with streptococcal ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Outcome of patients with streptococcal prosthetic joint infections with special reference to rifampicin combinations
Auteur(s) :
Fiaux, E [Auteur]
Service des maladies infectieuses et tropicales [Rouen]
Titecat, Marie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Robineau, O [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Lora-Tamayo, J [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
El Samad, Youssef [Auteur]
CHU Amiens-Picardie
Etienne, M [Auteur]
Service des maladies infectieuses et tropicales [Rouen]
Frebourg, N [Auteur]
CHU Rouen
Blondiaux, N [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Brunschweiler, B [Auteur]
CHU Amiens-Picardie
Dujardin, F [Auteur]
Université de Rouen Normandie [UNIROUEN]
Beltrand, Eric [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Loiez, Caroline [Auteur]
Université de Lille
Cattoir, Vincent [Auteur]
Université de Caen Normandie [UNICAEN]
Canarelli J, P [Auteur]
Université de Picardie Jules Verne [UPJV]
Hulet, C [Auteur]
Université de Caen Normandie [UNICAEN]
Valette, M [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Nguyen, S [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Caron, F [Auteur]
Université de Rouen Normandie [UNIROUEN]
Migaud, Henri [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Senneville, Eric [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Service des maladies infectieuses et tropicales [Rouen]
Titecat, Marie [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Robineau, O [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Lora-Tamayo, J [Auteur]
Hospital General Universitario "Gregorio Marañón" [Madrid]
El Samad, Youssef [Auteur]
CHU Amiens-Picardie
Etienne, M [Auteur]
Service des maladies infectieuses et tropicales [Rouen]
Frebourg, N [Auteur]
CHU Rouen
Blondiaux, N [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Brunschweiler, B [Auteur]
CHU Amiens-Picardie
Dujardin, F [Auteur]
Université de Rouen Normandie [UNIROUEN]
Beltrand, Eric [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Loiez, Caroline [Auteur]
Université de Lille
Cattoir, Vincent [Auteur]
Université de Caen Normandie [UNICAEN]
Canarelli J, P [Auteur]
Université de Picardie Jules Verne [UPJV]
Hulet, C [Auteur]
Université de Caen Normandie [UNICAEN]
Valette, M [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Nguyen, S [Auteur]
Centre Hospitalier Gustave Dron [Tourcoing]
Caron, F [Auteur]
Université de Rouen Normandie [UNIROUEN]
Migaud, Henri [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab]
Senneville, Eric [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Titre de la revue :
BMC infectious diseases
Nom court de la revue :
BMC Infect. Dis.
Numéro :
16
Date de publication :
2016-10-13
ISSN :
1471-2334
Mot(s)-clé(s) :
Mesh:Treatment Outcome
Mesh:Knee Prosthesis/adverse effects
Mesh:Humans
Mesh:Knee Joint/microbiology
Mesh:Middle Aged
Mesh:Streptococcal Infections/etiology
Mesh:Anti-Bacterial Agents/administration & dosage*
Mesh:Arthritis/drug therapy
Mesh:Hip Prosthesis/microbiology
Mesh:Prosthesis-Related Infections/drug therapy*
Mesh:Female
Mesh:Knee Joint/surgery
Mesh:Rifampin/administration & dosage*
Mesh:Male
Mesh:Streptococcal Infections/drug therapy*
Mesh:Aged
Mesh:Levofloxacin/administration & dosage
Mesh:Drug Therapy
Mesh:Combination
Mesh:Arthroplasty
Mesh:Replacement
Mesh:Knee/adverse effects*
Mesh:Prosthesis-Related Infections/diagnosis
Mesh:Aged
Mesh:80 and over
Mesh:Retrospective Studies
Mesh:Hip Prosthesis/adverse effects
Mesh:Knee Prosthesis/microbiology
Outcome
Rifampicin
Streptococcus spp
Risk factors
Prosthetic joint infection
Mesh:Knee Prosthesis/adverse effects
Mesh:Humans
Mesh:Knee Joint/microbiology
Mesh:Middle Aged
Mesh:Streptococcal Infections/etiology
Mesh:Anti-Bacterial Agents/administration & dosage*
Mesh:Arthritis/drug therapy
Mesh:Hip Prosthesis/microbiology
Mesh:Prosthesis-Related Infections/drug therapy*
Mesh:Female
Mesh:Knee Joint/surgery
Mesh:Rifampin/administration & dosage*
Mesh:Male
Mesh:Streptococcal Infections/drug therapy*
Mesh:Aged
Mesh:Levofloxacin/administration & dosage
Mesh:Drug Therapy
Mesh:Combination
Mesh:Arthroplasty
Mesh:Replacement
Mesh:Knee/adverse effects*
Mesh:Prosthesis-Related Infections/diagnosis
Mesh:Aged
Mesh:80 and over
Mesh:Retrospective Studies
Mesh:Hip Prosthesis/adverse effects
Mesh:Knee Prosthesis/microbiology
Outcome
Rifampicin
Streptococcus spp
Risk factors
Prosthetic joint infection
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background
Outcome of patients with streptococcal prosthetic joint infections (PJIs) is not well known.
Methods
We performed a retrospective multicenter cohort study that involved patients with total hip/knee prosthetic ...
Lire la suite >Background Outcome of patients with streptococcal prosthetic joint infections (PJIs) is not well known. Methods We performed a retrospective multicenter cohort study that involved patients with total hip/knee prosthetic joint (THP/TKP) infections due to Streptococcus spp. from 2001 through 2009. Results Ninety-five streptococcal PJI episodes (50 THP and 45 TKP) in 87 patients of mean age 69.1 ± 13.7 years met the inclusion criteria. In all, 55 out of 95 cases (57.9 %) were treated with debridement and retention of the infected implants with antibiotic therapy (DAIR). Rifampicin-combinations, including with levofloxacin, were used in 52 (54.7 %) and 28 (29.5 %) cases, respectively. After a mean follow-up period of 895 days (IQR: 395–1649), the remission rate was 70.5 % (67/95). Patients with PJIs due to S. agalactiae failed in the same proportion as in the other patients (10/37 (27.1 %) versus 19/58 (32.7 %); p = .55). In the univariate analysis, antibiotic monotherapy, DAIR, antibiotic treatments other than rifampicin-combinations, and TKP were all associated with a worse outcome. The only independent variable significantly associated with the patients’ outcomes was the location of the prosthesis (i.e., hip versus knee) (OR = 0.19; 95 % CI 0.04–0.93; p value 0.04). Conclusions The prognosis of streptococcal PJIs may not be as good as previously reported, especially for patients with an infected total knee arthroplasty. Rifampicin combinations, especially with levofloxacin, appear to be suitable antibiotic regimens for these patients.Lire moins >
Lire la suite >Background Outcome of patients with streptococcal prosthetic joint infections (PJIs) is not well known. Methods We performed a retrospective multicenter cohort study that involved patients with total hip/knee prosthetic joint (THP/TKP) infections due to Streptococcus spp. from 2001 through 2009. Results Ninety-five streptococcal PJI episodes (50 THP and 45 TKP) in 87 patients of mean age 69.1 ± 13.7 years met the inclusion criteria. In all, 55 out of 95 cases (57.9 %) were treated with debridement and retention of the infected implants with antibiotic therapy (DAIR). Rifampicin-combinations, including with levofloxacin, were used in 52 (54.7 %) and 28 (29.5 %) cases, respectively. After a mean follow-up period of 895 days (IQR: 395–1649), the remission rate was 70.5 % (67/95). Patients with PJIs due to S. agalactiae failed in the same proportion as in the other patients (10/37 (27.1 %) versus 19/58 (32.7 %); p = .55). In the univariate analysis, antibiotic monotherapy, DAIR, antibiotic treatments other than rifampicin-combinations, and TKP were all associated with a worse outcome. The only independent variable significantly associated with the patients’ outcomes was the location of the prosthesis (i.e., hip versus knee) (OR = 0.19; 95 % CI 0.04–0.93; p value 0.04). Conclusions The prognosis of streptococcal PJIs may not be as good as previously reported, especially for patients with an infected total knee arthroplasty. Rifampicin combinations, especially with levofloxacin, appear to be suitable antibiotic regimens for these patients.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Inflammatory digestive disease : pathophysiology and therapeutic targets developement
Date de dépôt :
2019-03-01T15:16:47Z
2020-05-04T07:44:57Z
2020-05-04T07:44:57Z
Fichiers
- s12879-016-1889-0.pdf
- Version éditeur
- Accès libre
- Accéder au document